Gross Profit Trends Compared: Vertex Pharmaceuticals Incorporated vs Alkermes plc

Vertex vs. Alkermes: A Decade of Gross Profit Growth

__timestampAlkermes plcVertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014170914000519428000
Thursday, January 1, 2015144942000906794000
Friday, January 1, 20162264240001491717000
Sunday, January 1, 20173357370002213533000
Monday, January 1, 20184924480002638058000
Tuesday, January 1, 20194777290003615063000
Wednesday, January 1, 20204658520005469383000
Friday, January 1, 20215698380006670200000
Saturday, January 1, 20228936870007850400000
Sunday, January 1, 202314103680008607000000
Monday, January 1, 202413123010009489600000
Loading chart...

Data in motion

Gross Profit Trends: Vertex Pharmaceuticals vs. Alkermes

In the competitive landscape of pharmaceuticals, understanding financial health is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outperformed Alkermes plc in terms of gross profit. From 2014 to 2023, Vertex's gross profit surged by over 1,500%, reaching approximately $8.6 billion in 2023. In contrast, Alkermes saw a more modest increase of around 726%, culminating in a gross profit of about $1.4 billion in the same year.

A Decade of Growth

Vertex's impressive growth trajectory highlights its strategic prowess in the biotech sector, particularly in the development of innovative treatments. Meanwhile, Alkermes, while growing, has faced challenges in scaling at the same pace. This comparison underscores the dynamic nature of the pharmaceutical industry, where innovation and strategic investments can lead to significant financial gains.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025